Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate

L G Wang1, X M Liu, J W Chiao

  • 1New York University Cancer Institute, New York University School of Medicine, New York, NY 10010, USA. Longgui.wang@med.NYU.edu

Carcinogenesis
|May 18, 2006
PubMed
Abstract

Insights

Phenethyl isothiocyanate (PEITC) inhibits prostate cancer growth by repressing androgen receptor (AR) transcription and expression. This natural compound shows promise for treating both hormone-sensitive and hormone-refractory prostate cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Natural Products Chemistry

Background:

  • Prostate cancer often becomes androgen-refractory after treatment.
  • Androgen receptor (AR) overexpression is linked to hormone-independent cancer growth.
  • Isothiocyanates from cruciferous vegetables may modulate AR, but mechanisms require clarification.

Purpose of the Study:

  • To investigate the mechanism of phenethyl isothiocyanate (PEITC) in regulating the androgen receptor (AR).
  • To evaluate PEITC's effects on androgen-dependent and independent prostate cancer cells.

Main Methods:

  • Utilized LNCaP (androgen-dependent) and LNCaP (AI) (androgen-independent, AR-overexpressing) prostate cancer cell lines.
  • Assessed cell growth inhibition using MTT assay.
  • Analyzed AR expression and transcription via real-time PCR and Western blotting.
  • Investigated AR promoter activity using reporter assays.
  • Examined Sp1 transcription factor activity through reporter assays, Western blotting, and electrophoretic mobility shift assay.

Main Results:

  • PEITC significantly inhibited growth in both cell lines with equal IC50 values.
  • PEITC repressed AR expression at both transcriptional and post-translational levels.
  • Transcriptional repression occurred via inhibition of the Sp1 transcription factor.
  • Post-translational regulation involved accelerated protein degradation.

Conclusions:

  • PEITC represses AR transcription and expression, leading to growth arrest in both androgen-dependent and independent prostate cancer cells.
  • PEITC's dual action on AR and growth attenuation suggests potential for preventing and inhibiting hormone-sensitive and refractory prostate cancer.
  • Isothiocyanates, including PEITC, may serve as therapeutic agents for prostate cancer.